Exploring the clinical utility of Oncotype DX in ER+/HER2-, N0 and N1 breast cancer patients: Insights from a Romanian cohort

被引：0

作者：

Blidaru, A. ^{[1
]}

Zob, D. ^{[2
]}

Schenker, M. ^{[3
]}

Onisim, A. ^{[4
]}

Bodale, C. ^{[5
]}

Curca, R. ^{[6
]}

Negru, S. ^{[7
]}

Oprean, C. ^{[7
]}

Curescu, P. ^{[8
]}

Gafton, B. ^{[9
]}

Volovat, S. ^{[9
]}

Mihaila, R. ^{[2
]}

Filip, G. ^{[10
]}

Median, D. ^{[11
]}

Dediu, M. ^{[12
]}

Chetroiu, D. ^{[13
]}

Pantelimon, I. ^{[14
]}

Costovici, C. ^{[15
]}

Viisoreanu, C. G. ^{[16
]}

Titirez, V. ^{[17
]}

Mateescu, D. ^{[17
]}

Gal, C. ^{[17
]}

Vremes, G. ^{[18
]}

Stanculeanu, D. -L. ^{[1
]}

Tsoulos, N. ^{[19
]}

Kapetsis, G. ^{[19
]}

Giannoulakis, S. ^{[19
]}

Sires, A.

Chirnogea, A. ^{[20
]}

Maxim, A. -I. ^{[20
]}

Iorga, P. ^{[21
]}

Jinga, D. -C. ^{[22
]}

Nitipir, C. ^{[23
]}

机构：

[1] Alexandru Trestioreanu Inst, Bucharest, Romania

[2] Bucharest Oncol Inst, Bucharest, Romania

[3] St Nectarie Oncol Ctr, Craiova, Romania

[4] Medisprof Cluj Napoca, Cluj Napoca, Romania

[5] Amethyst Cluj Napoca, Cluj Napoca, Romania

[6] Elysee Alba Iulia, Alba Iulia, Romania

[7] OncoHelp Timisoara, Timisoara, Romania

[8] Timisoara Municipal Hosp, Timisoara, Romania

[9] Reg Inst Oncol Iasi, Iasi, Romania

[10] Ponderas Acad Hosp Regina Maria, Bucharest, Romania

[11] FILANTROPIA Clin Hosp Bucharest, Bucharest, Romania

[12] Provita Med Grp, Bucharest, Romania

[13] Bucharest Univ Emergency Hosp, Bucharest, Romania

[14] Clin Hosp Dr Ion Cantacuzino, Bucharest, Romania

[15] CMDTAMP Bucharest, Bucharest, Romania

[16] MedLife Breast Inst, Bucharest, Romania

[17] Euroclin Hosp Regina Maria, Bucharest, Romania

[18] MedLife Titan Hosp, Bucharest, Romania

[19] Genekor SA, Athens, Greece

[20] Fundeni Clin Inst Bucharest, Bucharest, Romania

[21] Clin Emergency Hosp Bucharest, Bucharest, Romania

[22] Neolife Clin Bucharest, Bucharest, Romania

[23] Agrippa Ionescu Hosp, Bucharest, Romania

来源：

BREAST | 2025年 / 80卷

关键词：

D O I：

10.1016/j.breast.2025.103934

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P051

引用

页数：2

共 50 条

[21] Contemporary practice patterns for the use of regional nodal irradiation during post-lumpectomy radiotherapy for patients with N0/N1 breast cancer
Bergsma, Derek
Griffith, Kent
Jagsi, Reshma
Dominello, Michael
Boike, Thomas
Dilworth, Joshua
Bhatt, Amit
Vicini, Frank
Grubb, Maggie
Moran, Jean
Hayman, James
Pierce, Lori
CANCER RESEARCH, 2021, 81 (04)
[22] Addressing Unmet Need in the Management of Patients With ER+/HER2-, ESR1-Mutated Metastatic Breast Cancer: Clinician's Perspective
Rugo, Hope S.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (12) : 623 - 632
[23] A prospective clinical utility study of the impact of the 21-gene recurrence score (RS) assay in the treatment of estrogen receptor positive (ER+), HER2 negative (HER2-), 1-3 node positive (N plus ) breast cancer (BC)
Sun, Julia
Fenton, Dave
Baxter, Simon
Chan, Angela
Roberts, Sara
Feng, Xiaolan
Lohrisch, Caroline
Gelmon, Karen
Shenkier, Tamara
Chia, Stephen
CANCER RESEARCH, 2018, 78 (04)
[24] Protein tyrosine kinase activity in 350 T1/T2, N0/N1 breast cancer. Preliminary results
Bolla, M
RostaingPuissant, B
Bottari, SP
Chedin, M
MarronCharriere, J
Colonna, M
Berland, E
Chambaz, EM
EUROPEAN JOURNAL OF CANCER, 1995, 31A : 649 - 649
[25] Protein tyrosine kinase activity in 350 T1/T2, N0/N1 breast cancer. Preliminary results
Bolla, M
RostaingPuissant, B
Bottari, SP
Chedin, M
MarronCharriere, J
Colonna, M
Berland, E
Chambaz, E
BREAST CANCER RESEARCH AND TREATMENT, 1996, 39 (03) : 327 - 334
[26] The Oncotype Dx Assay in ER-Positive, HER2-Negative Breast Cancer Patients: A Real Life Experience from a Single Cancer Center
Thibodeau, Stephane
Voutsadakis, Ioannis A.
EUROPEAN JOURNAL OF BREAST HEALTH, 2019, 15 (03) : 163 - 170
[27] Is it necessary to sample the contralateral nodal stations by EBUS-TBNA in patients with lung cancer and clinical N0/N1 on PET-CT?
Serra, Pere
Centeno, Carmen
Sanz-Santos, Jose
Torky, Mohamed
Baeza, Sonia
Mendiluce, Leire
Martinez-Barenys, Carlos
Lopez de Castro, Pedro
Abad, Jorge
Rosell, Antoni
Andreo, Felipe
LUNG CANCER, 2020, 142 : 9 - 12
[28] Adjuvant chemotherapy guidance for pT1-3N0-1 breast cancer patients with HR+, HER2- subtype: a cohort study based on the SEER database
Wen, Nan
Qiu, Juanjuan
Xu, Li
Wang, Yu
Zhang, Jia
Xie, Yanyan
Lv, Qing
Du, Zhenggui
ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (24)
[29] In silico evaluation of the 12-gene molecular score (EndoPredict) and the recurrence score (Oncotype DX) as predictors of response to neo-adjuvant chemotherapy in estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer.
Soliman, Hatem Hussein
Robson, Mark E.
Wagner, Susanne
Flake, Darl D.
Schwartzberg, Lee Steven
Sharma, Priyanka
Magliocco, Anthony Martin
Kronenwett, Ralf
Lancaster, Johnathan M.
Lanchbury, Jerry S.
Gutin, Alexander
Gradishar, William John
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[30] Prevalence of pn2/n3 Disease in Postmenopausal Women with cn0 ER+/HER2-breast Cancer
Amlicke, Maire J.
Park, Jihye
Agala, Chris B.
Ray, Emily M.
Downs-Canner, Stephanie M.
Spanheimer, Philip M.
ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (SUPPL 2) : 376 - 376

← 1 2 3 4 5 →